Introduction: Proprotein convertase subtilisin/kexin 9 (PCSK9) plays a crucial role in breaking down the hepatic low-density lipoprotein receptor (LDLR), thereby influencing the levels of circulating low-density lipoprotein cholesterol (LDL-C). Consequently, inhibiting PCSK9 through suitable ligands has been established as a validated therapeutic strategy for combating hypercholesterolemia and cardiovascular diseases. Area covered: Patent literature claiming novel compounds inhibiting PCSK9 disclosed from 2018 to June 2023 available in the espacenet database, which contains more than 150 million patent documents from over 100 patent-granting authorities worldwide. Expert opinion: The undisputable beneficial influence of PCSK9 as a pharmacological target has prompted numerous private and public institutions to patent chemical frameworks as inhibitors of PCSK9. While several compounds have advanced to clinical trials for treating hypercholesterolemia, they have not completed these trials yet. These compounds must contend in a complex market where new, costly, and advanced drugs, such as monoclonal antibodies and siRNA, are prescribed instead of inexpensive and less potent statins.

Fassi, E., Citarella, A., Albani, M., Milano, E., Legnani, L., Lammi, C., et al. (2024). PCSK9 inhibitors: a patent review 2018-2023. EXPERT OPINION ON THERAPEUTIC PATENTS, 34(4), 245-261 [10.1080/13543776.2024.2340569].

PCSK9 inhibitors: a patent review 2018-2023

Legnani, L;
2024

Abstract

Introduction: Proprotein convertase subtilisin/kexin 9 (PCSK9) plays a crucial role in breaking down the hepatic low-density lipoprotein receptor (LDLR), thereby influencing the levels of circulating low-density lipoprotein cholesterol (LDL-C). Consequently, inhibiting PCSK9 through suitable ligands has been established as a validated therapeutic strategy for combating hypercholesterolemia and cardiovascular diseases. Area covered: Patent literature claiming novel compounds inhibiting PCSK9 disclosed from 2018 to June 2023 available in the espacenet database, which contains more than 150 million patent documents from over 100 patent-granting authorities worldwide. Expert opinion: The undisputable beneficial influence of PCSK9 as a pharmacological target has prompted numerous private and public institutions to patent chemical frameworks as inhibitors of PCSK9. While several compounds have advanced to clinical trials for treating hypercholesterolemia, they have not completed these trials yet. These compounds must contend in a complex market where new, costly, and advanced drugs, such as monoclonal antibodies and siRNA, are prescribed instead of inexpensive and less potent statins.
Articolo in rivista - Review Essay
CVD; hypercholesterolemia; LDL-C; patents; PCSK9;
English
11-apr-2024
2024
34
4
245
261
reserved
Fassi, E., Citarella, A., Albani, M., Milano, E., Legnani, L., Lammi, C., et al. (2024). PCSK9 inhibitors: a patent review 2018-2023. EXPERT OPINION ON THERAPEUTIC PATENTS, 34(4), 245-261 [10.1080/13543776.2024.2340569].
File in questo prodotto:
File Dimensione Formato  
Fassi-2024-Expert Opinion on Therapeutic Patents-VoR.pdf

Solo gestori archivio

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Tutti i diritti riservati
Dimensione 2.79 MB
Formato Adobe PDF
2.79 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/471898
Citazioni
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
Social impact